## Claims

This listing of the claims will replace all previous versions.

ď

- 1. (previously presented) An isolated and purified polypeptide which is a 90 kDa fragment of SEQ ID NO:32, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:61 and binds to B4 integrin.
- 2. (original) The polypeptide of claim 1, wherein the polypeptide has the sequence of SEQ ID NO:48.
- 3. (previously presented) An isolated and purified polypeptide which is a 35 kDa fragment of SEQ ID NO:32, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:61 and binds to B4 integrin.
- 4. (original) The polypeptide of claim 3, wherein the polypeptide has the sequence of SEQ ID NO:49.
- 5. (withdrawn) An isolated and purified polypeptide which is a fragment of SEQ ID NO:28, wherein said polypeptide has a molecular weight of about 35 kDa and comprises the amino acid sequence of SEQ ID NO:61.
- 6. (withdrawn) The polypeptide of claim 3, wherein the polypeptide has the sequence of SEQ ID NO:53.
- 7. (currently amended) A An isolated peptide of about 10 between 6 and 10 amino acids comprising SEQ ID NO:61.
- 8. (original) The peptide of claim 7 wherein the peptide sequence is selected from the group consisting of SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:52.
- 9. (withdrawn) A method for inhibiting metastatic tumor formation in an individual comprising the step of administering to the individual a peptide of about 10 amino acids comprising SEQ ID NO;61.
- 10. (withdrawn) The peptide of claim 9 wherein the peptide sequence is selected from the group consisting of SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:52.

- 11. (withdrawn) The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:50.
- 12. (withdrawn) The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:51.
- 13. (withdrawn) The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:52.
- 14. (withdrawn) The method of claim 9 wherein the metastatic tumor is a lung tumor.
- 15. (withdrawn) The method of claim 9, wherein the peptide is administered in combination with a pharmaceutically acceptable excipient.